San Francisco-based Epicrispr Biotechnologies is trying to develop gene-editing technology that would prevent a type of muscular dystrophy. The Lululemon founder contributed to the round through his charitable organization Solve FSHD. (The Logic)
San Francisco-based Epicrispr Biotechnologies is trying to develop gene-editing technology that would prevent a type of muscular dystrophy. The Lululemon founder contributed to the round through his charitable organization Solve FSHD. (The Logic)
San Francisco-based Epicrispr Biotechnologies is trying to develop gene-editing technology that would prevent a type of muscular dystrophy. The Lululemon founder contributed to the round through his charitable organization Solve FSHD. (The Logic)
Talking point: For Wilson, the investment is personal. The 69-year-old billionaire was diagnosed with facioscapulohumeral muscular dystrophy (FSHD) at age 32. He launched his philanthropy fund in 2022 with $100 million to back research and ideally find a cure for the disease. The treatment Epicrispr is developing aims to target the disease’s genetic cause, which leads muscles to waste away. The company—last valued at US$185 million in July 2022, according to PitchBook—plans to use the money for human clinical trials, with the first set to begin in New Zealand this year.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.